logo-loader
LON:NSCI

Netscientific PLC

Receive alerts
Market:
LON
Market Cap:
£5.3 m
Price
£0.07
Change
-3.57%
52 weeks high
29.90
52 weeks low
1.55

Viewing results 1-25 of 112

Health

NetScientific PLC portfolio company PDS Biotech agrees deal to raise up to US$20mln

The agreement will see the PDS direct Aspire Capital to buy up to 100,000 shares per day whenever the stock price exceeds 50 US cents...

on 31/7/19
Health

NetScientific rockets as ProAxsis sees positive early trial data for NEATstik lung disease test

The data, published in the peer-reviewed European Respiratory Journal, found that NEATstik was able to replicate the results of existing tests for chest infections within only ten minutes...

on 31/5/19
Health

NetScientific ‘confident’ in prospects of its three portfolio companies

Here we take a closer look at healthcare investor NetScientific PLC (LON:NSCI)...

on 24/5/19
Health

NetScientific to focus on extending lifespan as CEO reiterates confidence in portfolio firms

CEO Ian Postlethwaite said the healthcare commercialisation firm had taken measures to reduce its central function costs and was expected to have sufficient cash to operate until the end of 2020...

on 22/5/19
Health

Netscientific surges as peer-reviewed article confirms potential of PDS Biotech’s Versamune immunotherapy platform

In the article, researchers described how the Versamune platform recruits and activates killer T-cells to recognise and effectively attack cancer cells while simultaneously making cancer cells more susceptible to T-cell attack...

on 16/5/19
Health

NetScientific soars as it sells stakes in Vortex Biosciences and Wanda for £150,000

The group said after the close on 22 March that it would use the proceeds of the sale towards its ongoing working capital requirements...

on 25/3/19
Finance

NetScientific portfolio companies Vortex Biosciences and Wanda to be wound up

NetScientific also announced that PDS and Edge Therapeutics have completed their all-share merger...

on 18/3/19
Health

NetScientific unaware of any reason behind recent share price jump

The company is currently trying to reduce its costs “significantly” in order to invest as much of its remaining cash as possible into its portfolio companies...

on 14/3/19
Health

Netscientific expects shareholders to reject plan to delist from AIM and become private company

NetScientific has decided to postpone its general meeting. ...

on 1/3/19
Health

NetScientific to delist from AIM and become a private company following strategic review

The firm said that it had concluded following the review that a revised strategy was required to reduce its central functions and costs “significantly” so as much of its remaining cash as possible could be allocated to its portfolio companies...

on 15/2/19
Health

NetScientific says portfolio company Glycotest receives initial US$3mln tranche from Fosun Pharma

The group said the initial tranche will primarily serve to drive Glycotest's proprietary HCC Panel towards commercialisation in the US and to transfer the technology to Fosun...

on 14/2/19
Health

NetScientific says continuing to assess all remaining strategic options after closing formal sale process

The transatlantic healthcare IP commercialisation group announced on 26 November 2018 that it had decided to conduct a review of the various strategic options open to it, one of which was a sale...

on 15/1/19
Health

NetScientific mulling its options, including a delisting, as it waits for firm offers for its portfolio companies

The board believes that the market is undervaluing NetScientific's portfolio...

on 20/12/18
Health

NetScientific puts itself up for sale; says it’s feeling unloved by the market

Bosses believe the market is undervaluing the strength of NetScientific’s portfolio, and as such, thinks the best way to maximise shareholder value is to sell off all or parts of the business...

on 26/11/18
Health

NetScientific lifted as portfolio company PDS Biotechnology announces merger with Edge Therapeutics

The company said the all-share merger was expected to create a publicly traded biotech company specialising in immune-oncology and treatments for early and late-stage cancer...

on 26/11/18
Health

NetScientific portfolio company Vortex presents study to combine technology with impedance spectroscopy

The healthcare IP commercialisation group said the study introduced the coupling of Vortex’s technology with an impedance chip for counting and sizing cancer cells...

on 8/11/18
Health

NetScientific portfolio company Vortex enters manufacturing partnership with STRATEC

The firm said STRATEC would assist Vortex in producing a customised chip, a crucial component of its VTX-1 liquid biopsy platform...

on 1/11/18
Health

NetScientific surges after portfolio company Glycotest secures funding

Upon satisfaction of the contingent outbound direct investment approval, NetScientific's controlling interest will be 50.4% of Glycotest, calculated on a fully-diluted basis following the closing of the Series A Financing...

on 22/10/18
Health

NetScientific sees “key value inflection points” in next 12 months

In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago...

on 22/10/18
Health

NetScientific “pleased” with performance of portfolio companies as it narrows losses in first half

“We are pleased with the progress our portfolio companies have made in the first half of this year, and expect several key value inflection points to occur in the next 12 months”...

on 28/9/18
Health

NetScientific rises as ProAxsis products selected for large-scale respiratory study

The BRIDGE study, funded by the European Respiratory Society, will be conducted over three years and involve 1,000 patients suffering from bronchiectasis across Europe...

on 20/9/18
Health

NetScientific’s Wanda portfolio company launches new digital health app

Wanda’s technology uses machine learning to help healthcare providers better manage the risk and care of patients by predicting adverse events before they happen...

on 15/8/18
Health

NetScientific portfolio company ProAxsis awarded third CE mark for respiratory disease test

The investment firm said the mark, registered for ProAxsis' ProteaseTag Active Proteinase-3 Immunoassay, was accompanied by a first commercial sale of around £5,000...

on 2/8/18